Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia
oleh: Massimo Breccia, Giuseppe Cimino, Daniela Diverio, Fabiana Gentilini, Franco Mandelli, Francesco Lo Coco
| Format: | Article |
|---|---|
| Diterbitkan: | Ferrata Storti Foundation 2007-09-01 |
Deskripsi
We report here a preliminary experience with gemtuzumab ozogamicin (GO) used at low dosage (3 mg/m2) in 3 elderly patients with acute promyelocytic leukaemia (APL) who presented molecular relapse and were unfit for intensive chemotherapy.